|Day's Range||606.60 - 616.30|
|52 Week Range||571.90 - 854.95|
|PE Ratio (TTM)||20.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.
The U.S. Food and Drug Administration noted incomplete laboratory records among potential manufacturing violations it observed during an inspection of Sun Pharmaceutical Industries Ltd.’s Dadra unit this ...
India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.